



ELEVATION  
ONCOLOGY

# THE SUMMIT IS CLEAR

once you pass through the clouds

We believe that every patient deserves to know what is driving their cancer and which therapeutics can treat it.



## Genomic testing illuminates the path

Each tumor has a genomic fingerprint that may help physicians map the best path to overcoming it.

## Blazing the trail to make genomic insights actionable

We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer – no matter how rare.

## Our lead candidate **seribantumab** inhibits tumor growth driven by **NRG1 gene fusions**.

Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion. Learn more at [www.NRG1fusion.com](http://www.NRG1fusion.com).

ELEVATION ONCOLOGY – NOVEMBER 2020


*Elevating the treatment of cancer*

E00001-002-000



# ELEVATING PRECISION MEDICINE TO THE FOREFRONT OF EVERY CANCER TREATMENT JOURNEY

NRG1 fusions represent **the next summit** in the range of tumor-agnostic precision medicines:



## INVESTORS



## EXECUTIVE TEAM

**Shawn M. Leland, PharmD, RPh**  
Founder and Chief Executive Officer

**Sheila Magil, PhD**  
VP, CMC and Quality

**Amy C. Covers**  
VP, Medical Affairs

**Doug Plessinger, RPh**  
VP, Clinical Operations

**Siera Talbott, PhD, PMP**  
VP, Program Management & Strategic Alliances

## SCIENTIFIC ADVISORY BOARD

**Lori Kunkel, MD (Chair)**  
LAK505

**Sai-Hong Ignatius Ou, MD, PhD**  
UC Irvine

**David Ross Camidge, MD, PhD**  
University of Colorado

**Siraj M. Ali, MD, PhD**  
EQRx

**Alex Drilon, MD**  
MSKCC

## BOARD OF DIRECTORS

**Steve Elms (Chair)**  
Managing Partner, Aisling Capital

**Shawn M. Leland, PharmD, RPh**  
Founder and Chief Executive Officer, Elevation Oncology

**Lori Hu**  
Managing Director, Vertex Ventures HC

**Colin Walsh**  
Partner, Qiming Venture Partners USA

**Tim Clackson, PhD**  
President and EVP, Xilio Therapeutics

**Richard Gaster, MD, PhD**  
Partner, venBio Partners

**Andrew Phillips, PhD**  
Managing Director, Cormorant Asset Management